Treatment for obesity in the UK could become a two-tier system where the most vulnerable patients miss out altogether.

Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Meghan Trainor showed off her flat abs in a mirror selfie with coach Bella Maher after the pop star went through a weight ...

A groundbreaking study has compared the three top weight loss medications on the market, which has produced some surprising ...

Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.

Por TOM MURPHYEl mercado de tratamientos para la obesidad y la diabetes sigue siendo extremadamente activo, canalizando miles de millones de dólares en ventas para Eli Lilly y alimentando una ...

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...